| 拓扑替康单药治疗小细胞肺癌临床研究 |
| |
| 引用本文： | 黎莉,刘亚民,于学军,王永刚,张文东.拓扑替康单药治疗小细胞肺癌临床研究[J].中国肿瘤临床,2001,28(10):761-763. |
| |
| 作者姓名： | 黎莉 刘亚民 于学军 王永刚 张文东 |
| |
| 作者单位： | 山东大学齐鲁医院肿瘤中心化疗科, |
| |
| 摘 要： | 目的探讨拓扑替康单药治疗小细胞肺癌(SCLC)的疗效及安全性.方法初治和复治(SCLC)40例,可评价疗效35例,可评价不良反应40例.拓扑替康1.2mg·m
|
| 关 键 词： | 拓扑替康 小细胞肺癌 疗效 |
| 文章编号： | 1000-8179(2001)10-0761-03 |
| 修稿时间： | 2001年3月21日 |
Clinical Study on Topotecan as a Single Agent Therapy for Small Cell Lung Cancer |
| |
| Li Li Liu Yamin Yu Xuejun et al Section of Chemotherapy for Solid Tumors,Cancer Center,Qilu Hospital of Shandong University,Jinan.Clinical Study on Topotecan as a Single Agent Therapy for Small Cell Lung Cancer[J].Chinese Journal of Clinical Oncology,2001,28(10):761-763. |
| |
| Authors: | Li Li Liu Yamin Yu Xuejun Section of Chemotherapy for Solid Tumors Cancer Center Qilu Hospital of Shandong University Jinan |
| |
| Abstract: | Objective:To evaluate the efficacy and safety profile of topotecan as a single a-gent chemotherapy for small cell lung cancer.(SCLC).Methods:Forty cases of previously treated and untreated SCLC patients were enrolled.Thirty-five patients were evaluated for effica-cy and all40cases were evaluated for safety.Topotecan was given as a30-min intravenous in-fusion at the dose of1.2mg /m2/day for5days and21days as a course.Efficacy was evaluated after two courses.A third course was given to CR and PR patients.Results:Thirty-five pa-tients went through the treatment schedule with3CR,13PR with a total effective rate of45.7%.Bone marrow suppression was the dominate side effect.Non-hematological side effects were slight and tolerable.Conclusion:Topotecan appears to be an effective first-line or sec-ond-line chemotherapeutic agent for SCLC and more effective for previously untreated patients. |
| |
| Keywords: | Topotecan Small cell lung cancer Efficacy |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
